COMP <GO>
MRVI vs XNCR // ENTERPRISE SCALE & MARKET CAP
Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) VS. Xencor Inc. (NASDAQ) • 15-METRIC TALLY: MRVI 2
— XNCR 5
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRVI
LAST: $8.46 (-0.47%) • MKT CAP: $2.20B
market-cap
$2.20B
LAST: $29.21 (-2.60%) • MKT CAP: $2.17B
market-cap
$2.17B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRVI VS. XNCR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRVI | XNCR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -21.30% | -13.70 | XNCR | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.22% | -6.37% | +3.15 | MRVI | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -28.30% | 13.70% | -42.00 | XNCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.04 | 4.32 | -1.28 | XNCR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | XNCR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 68.0 | -14.41 | XNCR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.20B | $2.17B | $25.0M | MRVI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRVI REV | XNCR REV | MRVI GROSS % | XNCR GROSS % | MRVI FCF | XNCR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $185.7M | $125.6M | 18.3% | — | -$70.7M | -$138.3M |
| FY 2024 | $259.2M | $110.5M | 41.8% | — | -$22.2M | -$208.3M |
| FY 2023 | $288.9M | $174.6M | — | — | $126.2M | -$77.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRVI // BETA —
XNCR // BETA —